Fast In‑Bed Tracking (FIT) weight-loss program using a bed-integrated scale for wheelchair users

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional project pairs the Fast In‑Bed Tracking (FIT) Internet-of-Things bed scale with an adapted Group Lifestyle Balance program for people who use wheelchairs. Participants who meet inclusion criteria will join the GLB-AIM weight-loss program, and approximately half will receive the FIT bed-scale device integrated into their bed to passively capture weight. The trial compares weight-loss outcomes between participants using the FIT system plus the program versus the program without the bed scale over the intervention period. Enrollment is limited to adults who primarily use a wheelchair, meet BMI guidelines, have smartphone and internet access, and live within the local recruitment area near Pittsburgh.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age18 +
* Live within approximately 75 miles of Pittsburgh
* Uses a wheelchair as primary means of locomotion
* Currently transfers in and out of bed every night (or most nights)
* Has been diagnosed as obese or overweight
* Are interested in losing weight
* BMI in the range of approximately 25 to 40; BMI range will be determined from published evidence for the primary diagnosis of the participant. For example, spinal cord injury /quadriplegic BMI range of approximately 22 to 40; for amputees it will be based on location and level of amputation, or if no diagnosis specific evidence exists, a BMI of approximately 25 to 40 will be used as a general guideline.
* Own a smart phone, and have reliable internet and wifi connection
* Are comfortable using exercise equipment like resistance bands or hand pedal exercisers
* Are able and willing to engage in exercise of moderate intensity
* Weight in bed including sleep partner is an estimated combined weight of 600 pounds or less
* Does not have a regular way to weigh themselves, such as a roll-on scale in the home or gym, or have regular access to a device to weigh themselves regularly and are willing to avoid weighing themselves during the trial.
* Indication that the participant has autonomy in decision-making as determined by the "Everyday Autonomy Self-Determination Scale."
* Indication that their current bedroom setup is compatible with the FIT bed scales as determined by the "Bed Determination Survey."

Due to the medical complexity of this population, inclusion of this study based on BMI, in-bed transfer frequency, or geographic location will be at the discretion of the expert members of our study team and will be considered on a case-by-case basis.

Exclusion Criteria:

* Extended vacations or absences planned in the next year (more that 2 - 4 weeks) or plans to move approximately 75 miles or greater from the Pittsburgh region
* BMI outside of the desired range as based on condition and as determined by the study team.
* Currently taking weight loss medication, medications that affect appetite, or have had weight loss surgery in the last 2 years.
* History disordered eating in the last 2 years, such as Anorexia Nervosa, Bulimia Nervosa or Binge Eating Disorder
* Currently pregnant or intend to become pregnant in the next 12 months
* Regularly have 4 or more alcoholic drinks a day
* Have any cognitive conditions that limit decision making or self-governing.
* Indication that the participant does not have autonomy in decision-making as determined by the "Everyday Autonomy Self-Determination Scale."
* Indication that their current bedroom setup is not compatible with the FIT bed scales as determined by the "Bed Determination Survey."

Due to the medical complexity of this population, exclusion from this study based on BMI, geographic location, and what is considered a "medication that affects appetite" will be at the discretion of the expert members of our study team and will be considered on a case-by-case basis.

Where it's running

• University of Pittsburgh, Bakery Square, Department of Rehabilitation Science and Technology
  Pittsburgh, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Jonathan Pearlman, PhD — University of Pittsburgh
• Study coordinator: Daniel Rusnak, MS
• Email: dar27@pitt.edu
• Phone: 412-624-8575

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

• Monthly dose of PF-08653944 vs placebo in Chinese adults who are overweight or obese

  This study tests whether berobenatide (PF-08653944) given once a month helps adults in China lose weight compared with a placebo.

  Recruiting Phase 3 Pfizer · Hefei, Anhui and 5 other locations · NCT07874633

• FutureShape Family: a family-based weight-management program with semaglutide for children and parents

  This trial tests whether a family-centered program that combines a prescription medication (semaglutide) with lifestyle support and app-based coaching can help adults with obesity and their children who are overweight/obese.

  Recruiting Phase 4 University of Copenhagen · Copenhagen · NCT07872904

• Home self-administration of a weight-management medicine with an autoinjector in adults who are overweight or obese

  This study tests whether adults who are overweight or have obesity can successfully self-administer maridebart cafraglutide at home using an autoinjector.

  Recruiting at 25 sites Phase 3 Amgen · San Diego, California and 24 other locations · NCT07871409

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.